sofosbuvir/velpatasvir/voxilaprevir (Vosevi)
Jump to navigation
Jump to search
Indications
- treatment of hepatitis C genotypes 1-6 without cirrhosis (FDA-approved July 2017)
More general terms
Components
References
- ↑ FDA News Release. July 18, 2017 FDA approves Vosevi for Hepatitis C https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Bourliere M, Gordon SC, Flamm SL et al Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 Jun 1;376(22):2134-2146. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28564569 Free Article